| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC3066 | Ldt8 Dihydrochloride | Highly potent multi-target antagonists of alpha1A- and alpha1D-adrenoceptors, and 5-HT1A receptors |
|
| DCC3067 | Ledgf/p75-in Inhibitor-6d | Novel inhibitor of the LEDGF/p75-IN interaction, potently inhibiting both the early and late stages of HIV-1 replication |
|
| DCC3068 | Lefucoxib | Cyclooxygenase-2 (COX-2) inhibitor |
|
| DCC3069 | Lei-101 | Novel, orally available and peripherally restricted selective cannabinoid CB2 receptor agonist |
|
| DCC3070 | Lei-301 | Novel potent inhibitor for the PLAAT family members, reducing the NAE levels, including anandamide, in cells overexpressing PLAAT2 or PLAAT5 |
|
| DCC3071 | Lem-06 | Novel inhibitor of nuclear receptor binding SET domain 2 (NSD2), against H3K36 methylation |
|
| DCC3072 | Lenaldekar | Novel inhibitor of T-cell expansion and autoimmune encephalomyelitis |
|
| DCC3073 | Lenalidomide-slf | Novel Electrophilic PROTAC that degrades nuclear proteins by engaging DCAF16 |
|
| DCC3074 | Leniquinsin | Phosphodiesterase inhibitor, acting as a vasodilator and showing antihypertensive effects |
|
| DCC3075 | Leo-134310 | Novel non-steroidal glucocorticoid receptor agonist |
|
| DCC3076 | Leo-29102 | Novel Soft-Drug Inhibitor of Phosphodiesterase 4 (PDE4) for Topical Treatment of Atopic Dermatitis |
|
| DCC3077 | Leq-506 | Orally bioavailable Smoothened (Smo) antagonist |
|
| DCC3078 | Leucettamine A | Leukotriene B4 receptor antagonist |
|
| DCC3079 | leucinethiol | Inhibitor of ERAAP function |
|
| DCC3080 | Levallorphan Tartrate Salt | Partial agonist (antagonist) at mu and delta opioid receptors. |
|
| DCC3081 | Levcromakalim Phosphate | Watersoluble prodrug of Levcromakalim, being more chemically robust and efficacious at lowering IOP with once daily dosing in a normotensive mouse model. |
|
| DCC3082 | Levocarnitine Propionate Hydrochloride | Natural carnitine derivative, playing a role in mitochondrial metabolism and demonstrating beneficial cardiovascular effects |
|
| DCC3083 | Levofloxacin Lactate | Respiratory quinolone antibiotic, exhibiting enhanced activity against the important respiratory pathogen Streptococcus pneumoniae |
|
| DCC3084 | Ginsenoside Rg | Neuroprotective, anti-inflammatory, and anti-diabetic agent, protecting against DNA damage and apoptosis induced by ultraviolet light |
|
| DCC3085 | levormeloxifene Fumarate | Selective estrogen receptor modulator (SERM) |
|
| DCC3086 | Lfcinb6 | Hematologic malignancy-selective membranolytic peptide from the antimicrobial core (RRWQWR) of bovine lactoferricin |
|
| DCC3087 | Lfs-829 | Novel potent and selective antagonist of exportin-1, attenuating dual NF-κB signaling and the Nrf2 cytoprotection pathway via targeting exportin-1 in colitis mice |
|
| DCC3088 | lg190178 | Novel non-secosteroidal vitamin D receptor (VDR) ligand |
|
| DCC3089 | Lgh00031 | Novel irreversible inhibitor of cell division cycle 25B, inhibiting human cancer cells via ROS generation |
|
| DCC3090 | Lgh447 Hydrochloride | Potent and specific pan-PIM inhibitor, inhibiting proliferation of several AML cell lines, showing dual antitumoral and bone antiresorptive effects |
|
| DCC3091 | Lh65.3 | Novel S. typhimurium infection inhibitor on the activity of DUSP3, DUSP11, and DUSP27 |
|
| DCC3092 | Lh-708 | Novel inhibitor of cystine stone formation for treatment of cystinuria |
|
| DCC3093 | L-histidinol Dihydrochloride | Natural precursor of histamine; reversible inhibitor of protein synthesis |
|
| DCC3094 | liafensine | Serotonin-norepinephrine-dopamine triple reuptake inhibitor (SNDRI); Anti-depressant |
|
| DCC3095 | liarozole Hydrochloride | Novel inhibitor of AMA1–RON2 interaction, blocking merozoite invasion from schizont-infected RBCs; Cytochrome P450 inhibitor |
|
